Dr. Kambhampati on the Potential of CAR T-Cell Therapy in CLL

Video

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL).

CAR T-cell therapy has shown strong efficacy in other hematologic malignancies such as acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. Now, it’s in the beginning stages of exploration in CLL, explains Kambhampati. Investigators from the University of Pennsylvania presented some compelling data with ibrutinib (Imbruvica), which is traditionally not associated with deep remissions. However, priming patients with ibrutinib for up to 6 months followed by CAR T-cell therapy infusions led to deeper remissions and minimal residual disease-negative status fairly early on, says Kambhampati.

Kambhampati himself has cared for patients enrolled in the trial and can speak first-hand to this groundbreaking research. If this research moves forward, he hopes that physicians will see an earlier introduction of cellular therapies in CLL.

Recent Videos
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Related Content
© 2025 MJH Life Sciences

All rights reserved.